Breakthrough biologics battle standard lupus treatment in kidney trial
NCT ID NCT07340463
Summary
This study compares two newer biologic drugs (belimumab and telitacicept) against the current standard treatment for lupus nephritis, a serious kidney complication of lupus. Fifty patients with active kidney inflammation will receive either a biologic drug alone, standard therapy, or a combination of both for six months. Researchers want to see which approach best improves kidney function while monitoring safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Research Ethics Committee of the General Hospital of Eastern Theater Command of the People's Liberation Army
RECRUITINGNanjing, Jiangsu, 210016, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.